A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Conditions

• Graft-versus-host Disease (GVHD)

Interventions

• DRUG: Ruxolitinib
• DRUG: Extracorporeal photopheresis (ECP)
• DRUG: Low-dose methotrexate (MTX)
• DRUG: Mycophenolate mofetil (MMF)
• DRUG: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
• DRUG: Infliximab
• DRUG: Rituximab
• DRUG: Pentostatin
• DRUG: Imatinib
• DRUG: Ibrutinib

Sponsor

Incyte Corporation